- Heartburn Slideshow: Foods to Eat, Foods to Avoid
- 10 Facts About the Amazing Brain
- Weight Gain Shockers Slideshow Pictures
What is Zemaira, and how does it work?
Zemaira increases antigenic and functional (anti-neutrophil elastase capacity [ANEC]) serum levels and lung epithelial lining fluid (ELF) levels of A1-PI.
Clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with Zemaira are not available.
The effect of augmentation therapy with Zemaira or any A1-PI product on pulmonary exacerbations and on the progression of emphysema in A1-PI deficiency has not been demonstrated in randomized, controlled clinical studies.
Zemaira is not indicated as therapy for lung disease patients in whom severe A1-PI deficiency has not been established.
What are the side effects of Zemaira?
The most common adverse reactions (ARs) occurring in at least 5% of subjects receiving Zemaira in all pre-licensure clinical trials were
- upper respiratory infection,
- cough increased,
- injection site hemorrhage,
- sore throat, and
Serious adverse reactions reported following administration of Zemaira in pre-licensure clinical trials included one event each in separate subjects of bronchitis and dyspnea, and one event each in a single subject of chest pain, cerebral ischemia and convulsion.
In post-licensure trials, the exposure adjusted incidence rate (EAIR) of serious exacerbations of chronic obstructive pulmonary disease (COPD) among subjects was higher during the RAPID Extension trial as compared to the rate observed during the preceding RAPID trial [see Clinical Trials Experience below].
Serious adverse reactions identified during postmarketing use were hypersensitivity reactions.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The following clinical trials were conducted with Zemaira:
- Controlled, double-blind trial in 44 subjects, who received a weekly 60 mg/kg body weight dose of either Zemaira (30 subjects) or Prolastin® (a commercially available Alpha1-Proteinase Inhibitor [Human] product) (14 subjects) for 10 weeks, followed by an open-label phase in which 43 subjects received Zemaira weekly for 14 weeks;
- Open-label trial in 9 subjects who received a weekly 60 mg/kg body weight dose of Zemaira for 26 weeks, followed by a 7-week to 22-week extension;
- Crossover, double-blind trial in 18 subjects who received a single 60 mg/kg dose of Zemaira and a single 60 mg/kg dose of Prolastin;
- Open-label trial of 19 subjects who received a single 15 mg/kg (2 subjects), 30 mg/kg (5 subjects), 60 mg/kg (6 subjects), or 120 mg/kg (6 subjects) dose of Zemaira; and Post-Licensure Randomized, Placebo-Controlled Trial of Augmentation Therapy in Alpha-1 Protease Inhibitor Deficiency (RAPID), in 180 subjects who received a weekly 60 mg/kg body weight dose of either Zemaira (93 subjects) or placebo (87 subjects) for 24 months (referred to as years 1 and 2 in Table 3).
- Post-Licensure Open-label extension of the RAPID trial involving 140 subjects who had completed blinded treatment with Zemaira or placebo for 24 months in the RAPID trial and who entered the extension trial and received open-label Zemaira for up to an additional 24 months (referred to as years 3 and 4 in Table 3).
Table 1 summarizes the ARs, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in prelicensure clinical trials of Zemaira.
Table 1: Overall Adverse Reactions (ARs) and Serious
|Number of Subjects* (Events per Sub-ject-Year†)||Number of Infusions‡ (% of all Infusions)|
|ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).||54 (5.6)||16 (3.8)||160 (12.3)||31 (19.4)|
|Serious ARs (Serious AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).||4 (0.2)||1 (1.0)||6 (0.5)||1 (0.6)|
|* Based on unique subjects. If a subject experienced more
than one AR, the subject was only counted once.
† The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database.
‡ If there were multiple occurrences of ARs following a single infusion, only one occurrence was counted.
Table 2 summarizes the ARs occurring in 5% or more ( > 3) subjects, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in clinical trials of Zemaira.
Table 2: Adverse Reactions Occurring in ≥ 5% of
|ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).||Number of Subjects* (Events per Sub-ject-Year†)||Number of Infusions‡ (% of all Infusions)|
|Headache||13 (0.7)||5 (1.3)||19 (1.5)||5 (3.1)|
|Sinusitis||10 (0.5)||1 (0.3)||13 (1.0)||1 (0.6)|
|Upper Respiratory Infection||10 (0.4)||1 (0.3)||10 (0.8)||1 (0.6)|
|Bronchitis||5 (0.2)||0 (0.0)||6 (0.5)||0 (0.0)|
|Asthenia||5 (0.2)||2 (0.5)||5 (0.4)||2 (1.3)|
|Cough Increased||5 (0.2)||1 (0.5)||5 (0.4)||2 (1.3)|
|Fever||4 (0.1)||0 (0.0)||4 (0.3)||0 (0.0)|
|Injection Site Hemorrhage||4 (0.1)||0 (0.0)||4 (0.3)||0 (0.0)|
|Rhinitis||4 (0.1)||0 (0.0)||4 (0.3)||0 (0.0)|
|Sore Throat||4 (0.1)||0 (0.0)||4 (0.3)||0 (0.0)|
|Vasodilation||4 (0.1)||1 (0.3)||4 (0.3)||1 (0.6)|
|* Based on unique subjects. If a subject experienced more
than one AR of the same type, the subject was only counted once.
†The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database.
‡ If more than one of the same type of an event occurred after an infusion, only one event was counted.
Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
- In a retrospective analysis, during the 10-week blinded portion of the 24-week clinical trial, 6 subjects (20%) of the 30 treated with Zemaira had a total of 7 exacerbations of their chronic obstructive pulmonary disease (COPD).
- Nine subjects (64%) of the 14 treated with Prolastin had a total of 11 exacerbations of their COPD. The observed difference between groups was 44% (95% confidence interval [CI] from 8% to 70%).
- Over the entire 24-week treatment period, of the 30 subjects in the Zemaira treatment group, 7 subjects (23%) had a total of 11 exacerbations of their COPD.
- In the 24-week double-blind trial, Zemaira-treated subjects were tested for HAV, HBV, HCV, HIV, and parvovirus B19 (B19V), and no evidence of virus transmission was observed.
- In the RAPID study 25 serious exacerbations of COPD were reported in 15 Zemaira subjects vs. 17 such events in 9 placebo subjects, corresponding to rates of 0.146 exacerbations per subject-year with Zemaira and 0.115 exacerbations per subject-year with placebo, (ratio Zemaira:Placebo [95% confidence interval]: 1.256 [0.457 - 3.454]).
- Subjects who were randomized to Zemaira in the 2-year RAPID trial who then entered and received open-label Zemaira in the 2 year RAPID extension trial were in the “Early Start” group. Subjects who were randomized to Placebo in the 2-year RAPID trial who then entered and received open-label Zemaira in the 2 year RAPID extension trial were in the “Delayed Start” group.
- During the RAPID Extension trial 37 serious exacerbations of COPD were reported in 19 subjects (25%) in the Early Start group, corresponding to rates of 0.25 exacerbations per subject-year.
- In comparison, 20 serious exacerbations were reported in 11 subjects (17%) in the Delayed Start group corresponding to rates of 0.16 exacerbations per subject-year (ratio Early: Delayed [95% confidence interval]: 1.58 [0.68 – 3.66], Table 3).
- Among the Early Start subjects who entered the RAPID extension trial (N = 76), the exposure adjusted incidence rate of serious exacerbations during the RAPID extension trial (years 3-4) was 0.25 compared to 0.12 for those subjects during the earlier RAPID trial(years 1-2), (ratio RAPID Extension:RAPID: 2.10 [95% confidence interval: 1.21 – 3.67]).
- Among the Delayed Start subjects who entered the RAPID extension trial (N = 64), the exposure adjusted incidence rate of serious exacerbations during the RAPID extension trial (years 3-4) was 0.16 compared to 0.10 for those subjects during the earlier RAPID trial (years 1-2), (ratio RAPID Extension:RAPID: 1.56 [95% confidence interval: 0.80 – 3.03]).
Table 3: Comparison of Exposure-Adjusted Incidence
Rates for Serious COPD Exacerbations Occurring in the RAPID study between
Zemaira and Placebo subjects and in the RAPID Extension Studies between Early
Start and Delayed Start subjects
|Serious COPD Exacer- bations*||Episode||n||%||EAIR (95% CI)||Episode||n||%||EAIR 95% CI||Treatment Ratio for EIAR (95% CI)*|
|RAPID Study (Years 1 - 2)||Zemaira (N = 93)||Placebo (N = 87)||Zemaira: Placebo|
|25||15||16.1||0.15 (0.10 -0.22)||17||9||10.3||0.12 (0.07 -0.18)||1.26 (0.46 -3.45)|
|Extension Study (Years 3 - 4)||Early Start† (N = 76)||Delayed Start‡ (N = 64)||Early: Delayed|
|37||19||25.0||0.25 (0.18 -0.35)||20||11||17.2||0.16 (0.10 -0.25)||1.58 (0.68 -3.66)|
|N = total number of safety subjects, n = number of
subjects within a category, % = (n/N)*100, CI = Confidence Interval. Subject
time at risk: Zemaira = 171.14 years, Placebo = 147.75 years, Early Start Group
= 146.46 years, Delay Start Group = 124.71 years.
EAIR = Exposure-Adjusted Incidence Rate (events/subject time at risk). The point estimates and confidence intervals for
EAIR values were calculated using negative binomial models.
*Episode = Serious exacerbations of COPD identified by investigators as meeting the Anthonisen criteria1 plus Serious Adverse Event (SAE) terms COPD, Condition Aggravated, Bronchitis, Lower Respiratory Tract Infection, Pneumonia. Serious exacerbation events that overlap or occur within 1 day of one another were counted as single exacerbation episodes.
†Early Start Group subjects were randomized to Zemaira during the double-blind RAPID trial (years 1-2) and received open-label Zemaira during the RAPID extension trial (years 3-4).
‡Delayed Start Group subjects were randomized to Placebo during the double-blind RAPID trial (years 1-2) and received open-label Zemaira during the RAPID extension trial (years 3-4).
- As with all therapeutic proteins, there is potential for immunogenicity. No anti-A1PI antibodies have been detected in clinical trials of Zemaira. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
- Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
- For these reasons, comparison of the incidence of antibodies to Zemaira with the incidence of antibodies to other products may be misleading.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.
Table 4 lists the ARs that have been identified during postmarketing use of Zemaira. This list does not include reactions already reported in clinical trials with Zemaira [see Clinical Trials Experience above].
Table 4: ARs Reported During the Postmarketing Use of
|System Organ Class||Preferred Term/Symptoms|
|Blood and lymphatic system disorders||Lymph node pain|
|General disorders and administration site conditions||Chills, infusion site reactions, facial, periorbital, lip and extremity swelling, chest pain|
|Immune system disorders||Hypersensitivity, anaphylactic reactions, tachycardia, hypotension, confusion, syncope, oxygen consumption decreased, pharyngeal edema|
|Nervous system disorders||Hypoesthesia, paresthesia, dizziness|
|Skin disorders||Hyperhidrosis, pruritus, rash including exfoliative and generalized, urticaria|
What is the dosage for Zemaira?
For Intravenous Use After Reconstitution Only.
The recommended dose of Zemaira is 60 mg/kg body weight administered once weekly. Dose ranging studies using efficacy endpoints have not been performed with Zemaira or any A1-PI product.
Is Zemaira safe to use while pregnant or breastfeeding?
Zemaira is an alpha1-proteinase inhibitor (A1-PI) indicated for chronic augmentation and maintenance therapy in adults with A1-PI deficiency and clinical evidence of emphysema.
Multimedia: Slideshows, Images & Quizzes
COPD (Chronic Obstructive Pulmonary Disease) Quiz
COPD is a combination of three conditions? Take this quiz to learn the three conditions that make up the pulmonary disease called...
COPD Foods to Boost Your Health - COPD Diet Tips
Boost your energy and combat COPD with these diet tips. Which foods can help patients with COPD? Which foods to avoid for COPD?...
COPD Lung Symptoms, Diagnosis, Treatment
COPD is a pulmonary disorder caused by obstructions in the airways of the lungs leading to breathing problems. Learn about COPD...
10 Smart Exercises for People With COPD: Pictures
The more you exercise, the better you'll feel with COPD. Breathe easier with these 10 exercises from WebMD.
Related Disease Conditions
COPD (Chronic Obstructive Pulmonary Disease)
COPD or chronic obstructive pulmonary disease is a lung condition caused by smoking tobacco, exposure to secondhand smoke, and/or air pollutants. Conditions that accompany COPD include chronic bronchitis, chronic cough, and emphysema. Symptoms of COPD include shortness of breath, wheezing, and chronic cough. Treatment of COPD includes GOLD guidelines, smoking cessation, medications, and surgery. The life expectancy of a person with COPD depends on the stage of the disease.
Emphysema, Chronic Bronchitis, and Colds
If you have a COPD such as emphysema, avoiding chronic bronchitis and colds is important to avoid a more severe respiratory infection such as pneumonia. Avoiding cigarette smoking, practice good hygeine, stay away from crowds, and alerting your healthcare provider if you have a sinus infection or cold or cough that becomes worse. Treatment options depend upon the severity of the emphysema, bronchitis, or cold combination.
Emphysema is a COPD (chronic obstructive pulmonary disease) that often occurs with other obstructive pulmonary problems and chronic bronchitis. Causes of emphysema include chronic cigarette smoking, exposure to secondhand smoke, air pollution, and in the underdeveloped parts of the world. Symptoms of emphysema include chronic cough, chest discomfort, breathlessness, and wheezing. Treatments include medication and lifestyle changes.
COPD vs. Asthma (Differences and Similarities)
COPD (chronic obstructive pulmonary disease) and asthma both have common symptoms like coughing, wheezing, shortness of breath, and a tight feeling in the chest. COPD is caused by tobacco smoking, while asthma is caused by your inherited genetic makeup and their interactions with the environment. Risk factors for asthma are obesity, exposure to cigarette smoke (even secondhand smoke), and personal history of hay fever. There is no cure for either disease, but symptoms can be managed with medication. A person with asthma has a better prognosis and life expectancy than someone with COPD.
COPD vs. Emphysema
COPD (chronic obstructive pulmonary disease) is the term doctors and other healthcare professionals use to describe a group of serious, progressive (worsens over time), chronic lung diseases that include emphysema, chronic bronchitis, and sometimes asthma. The number one cause of COPD or emphysema, is smoking, and smoking is the third leading cause of death in the US.
What are the Four Stages of COPD?
COPD (chronic obstructive pulmonary disease) is a group of diseases that cause an inflammatory reaction and irreversible damage in the lungs. The result is obstruction of normal airflow and breathing difficulties. COPD is a lifelong condition with periods of flare ups, and is not curable in any stage of the disease. Emphysema and chronic bronchitis are the most common diseases that make up COPD.
Can People With COPD Get Better?
Chronic obstructive pulmonary disease (COPD) is not curable in any stage of the disease. With early diagnosis and treatment, disease progression and flare-ups can be controlled.
End-Stage COPD: Signs, Symptoms, and Prognosis
Chronic obstructive pulmonary disease (COPD) is a group of diseases causing an inflammatory reaction and irreversible damage to the lungs. They cause obstruction of airflow and difficulty breathing.
Treatment & Diagnosis
- COPD (Chronic Obstructive Pulmonary Disease) FAQs
- Can Patients With Emphysema Benefit From Lung Volume Reduction Surgery?
- Emphysema from Crack Cocaine?
- Does Black Lung Disease Cause Emphysema?
- Is it Common to Have Pneumothorax with COPD?
- What Is Stage IV COPD?
- Emphysema Treatment
- Emphysema Causes and Risk Factors
- Emphysema Symptoms
Medications & Supplements
Latest Lungs News
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.